STOCK TITAN
  1. Home
  2. News
  3. TEVA

Teva- Pharmaceutical Industries Ltd. - TEVA STOCK NEWS

Welcome to our dedicated news page for Teva- Pharmaceutical Industries Ltd. (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva- Pharmaceutical Industries Ltd..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Teva- Pharmaceutical Industries Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Teva- Pharmaceutical Industries Ltd.'s position in the market.

News
Teva Announces Intention to Divest API Business as Part of Pivot to Growth Strategy
Rhea-AI Summary
Teva announced its intention to divest its active-pharmaceutical ingredient (API) business, or 'TAPI', to focus on core business strengths, capital allocation towards growth and innovation, and better serve patients. The divestiture is expected to enhance TAPI's position as a global leader in the growing API market and create additional value for Teva’s shareholders and stakeholders. The intended divestiture is expected to be completed in the first half of 2025, subject to reaching a satisfactory agreement on transaction terms with a prospective purchaser and the approval of an agreed transaction by Teva’s Board of Directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.15%
Tags
none
-
News
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance at 8 a.m. ET on January 31, 2024
Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will release its fourth quarter and full year 2023 financial results and financial guidance for 2024 on January 31, 2024. A conference call and live webcast will follow the release at 8:00 a.m. ET. Participants can register in advance for the call and access the webcast on Teva's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.62%
Tags
conferences earnings
-
News
Teva to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announces CEO's participation in the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
conferences
News
Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma
Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. (TEVA) and Biolojic Design Ltd. announced an exclusive license agreement to develop a potential novel antibody-based therapy for the treatment of Atopic Dermatitis and Asthma. BD9, a dual specific antibody, has the potential to target IL-13 / TSLP and treat inflammatory diseases such as atopic dermatitis and asthma. This collaboration supports Teva's Pivot to Growth strategy and aims to enhance the company's early-stage pipeline through strategic partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
none
-
News
New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity
Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. (TEVA) reports that a post hoc analysis of two phase 3 clinical studies presented at the European Headache Congress has shown the effectiveness of the migraine prevention treatment AJOVY® (fremanezumab) in reducing migraine attacks in patients with migraine and co-morbid obesity. The analysis compared the safety and efficacy of fremanezumab migraine preventive treatment in obese migraine patients vs normal weight migraine patients for a period of 6 months. After 6 months of treatment, monthly migraine days in migraine patients with high BMI was reduced to 6.8 vs 7.2 for normal weight patients. Adverse events in patients with obesity were similar to non-obese patients treated with fremanezumab.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
clinical trial
-
News
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
Rhea-AI Summary
Teva Pharmaceuticals (TEVA) closes collaboration deal with Sanofi (SAN, SNY) to co-develop and co-commercialize asset TEV '574, currently in Phase 2b clinical trials for ulcerative colitis and Crohn's disease. Teva to receive $500 million upfront payment and up to $1 billion in milestones. Joint development and profit sharing agreement with Sanofi. Estimated 10 million people worldwide live with IBD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
none
News
Teva to Present at the 6th Annual Evercore ISI HealthCONx Conference
Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) to present at Evercore ISI HealthCONx Conference on November 28, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
conferences
-
News
Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.
Rhea-AI Summary
Teva Pharmaceuticals Inc. (TEVA) receives approval for a generic version of Forteo® (teriparatide injection) to treat osteoporosis in the US, showcasing their strengths in complex generic formulations development and device engineering. The market availability of the product is expected in the coming weeks. The approval aims to enhance access to a critical treatment option for patients, aligning with Teva's strategic goal of sustaining a generic powerhouse.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.31%
Tags
none
-
News
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) collaborates with Royalty Pharma plc (Nasdaq: RPRX) to accelerate the clinical research program for olanzapine LAI (TEV-‘749) by receiving up to $125 million in funding. Olanzapine LAI is a long-acting subcutaneous injectable olanzapine for schizophrenia currently in Phase 3. The collaboration aims to support the development of this potential first long-acting olanzapine with a favorable safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
none
News
Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) reported Q3 2023 revenues of $3.9 billion, reflecting a 7% increase from Q3 2022, with a revised 2023 outlook of $15.1 - $15.5 billion. Strong performance of AUSTEDO®, AJOVY®, and the global generics business drove revenue growth. Non-GAAP diluted EPS was $0.60, with cash flow generated from operating activities of $5 million and free cash flow of $229 million. Exclusive collaboration with Sanofi on Anti TL1-A (TEV-‘574) and accelerated Phase 3 results for Olanzapine LAI (TEV-‘749) were highlighted. Teva api's new CEO and management team were announced.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
earnings
Stock TEVA logo
Teva- Pharmaceutical Industries Ltd.

NYSE:TEVA

TEVA Rankings

#632 Ranked by Market Cap
#2611 Ranked by Stock Gains
N/A Ranked by Dividends

TEVA Stock Data

15.63B
1.12B
53.13%
1.03%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Israel
P O B 3190

About TEVA

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.